Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
17.10
+0.61 (+3.70%)
Streaming Delayed Price
Updated: 12:38 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus Inc
< Previous
1
2
3
4
5
6
7
Next >
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Recap: Evolus Q4 Earnings
March 07, 2024
Via
Benzinga
Earnings Outlook For Evolus
March 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
February 14, 2024
A Relative Strength Rating upgrade for AbbVie shows improving technical performance.
Via
Investor's Business Daily
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
January 17, 2024
Via
Investor Brand Network
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From
Evolus
Via
Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From
Evolus
Via
Business Wire
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
February 01, 2024
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level.
Via
Investor's Business Daily
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 29, 2024
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped...
Via
Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
January 29, 2024
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
January 17, 2024
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 17, 2024
Via
Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Evolus
Via
Business Wire
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing...
Via
Benzinga
Exposures
Product Safety
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From
Evolus
Via
Business Wire
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From
Evolus
Via
Business Wire
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to...
Via
Benzinga
Exposures
Product Safety
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.